克拉霉素和14-羟基克拉霉素与阿莫西林或次水杨酸铋对幽门螺杆菌的体外协同试验。
In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori.
作者信息
Meyer J M, Ryu S, Pendland S L, Danziger L H
机构信息
College of Pharmacy, University of Illinois, Chicago 60612, USA.
出版信息
Antimicrob Agents Chemother. 1997 Jul;41(7):1607-8. doi: 10.1128/AAC.41.7.1607.
Abstract
The activity of clarithromycin-14-hydroxyclarithromycin (2:1 ratio) and bismuth subsalicylate or amoxicillin against Helicobacter pylori was determined by the checkerboard technique in vitro. Clarithromycin-14-hydroxyclarithromycin and amoxicillin resulted in additive effects in 7 of 22 isolates, compared to 14 of 22 isolates when bismuth subsalicylate was substituted for amoxicillin. Synergy was not demonstrated and is probably not responsible for the clinical success of treatment combinations containing clarithromycin.
摘要
采用棋盘稀释法在体外测定了克拉霉素-14-羟基克拉霉素（2:1比例）与次水杨酸铋或阿莫西林对幽门螺杆菌的活性。克拉霉素-14-羟基克拉霉素与阿莫西林联合使用时，22株分离株中有7株呈现相加作用；而用次水杨酸铋替代阿莫西林时，22株分离株中有14株呈现相加作用。未显示出协同作用，含克拉霉素的治疗组合临床疗效可能并非归因于协同作用。
相似文献
1
In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori.克拉霉素和14-羟基克拉霉素与阿莫西林或次水杨酸铋对幽门螺杆菌的体外协同试验。
Antimicrob Agents Chemother. 1997 Jul;41(7):1607-8. doi: 10.1128/AAC.41.7.1607.
2
Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori.三联疗法无效，两种不同铋剂四联方案作为幽门螺杆菌一线治疗选择的比较。
Saudi J Gastroenterol. 2016 Sep-Oct;22(5):366-369. doi: 10.4103/1319-3767.191141.
3
Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens.体外抗生素耐药性对治疗的影响：含铋剂方案
Can J Gastroenterol. 2000 Nov;14(10):885-9. doi: 10.1155/2000/709640.
4
Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori.
J Antimicrob Chemother. 1994 Dec;34(6):1025-9. doi: 10.1093/jac/34.6.1025.
5
Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori.氯化锌与碱式水杨酸铋对幽门螺杆菌临床分离株抗菌活性的比较。
Microb Drug Resist. 2014 Aug;20(4):305-9. doi: 10.1089/mdr.2013.0086. Epub 2013 Jul 11.
6
High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.14 天三联疗法为基础的含铋四联疗法对初始幽门螺杆菌根除的高疗效。
Helicobacter. 2010 Jun;15(3):233-8. doi: 10.1111/j.1523-5378.2010.00758.x.
7
Kill kinetics of antimicrobial agents against Helicobacter pylori.抗菌剂对幽门螺杆菌的杀灭动力学
J Antimicrob Chemother. 1996 Oct;38(4):719-25. doi: 10.1093/jac/38.4.719.
8
Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model.使用体外药效学模型评估克拉霉素和14-羟基克拉霉素对三株流感嗜血杆菌的抗菌活性。
Antimicrob Agents Chemother. 1994 Sep;38(9):2003-7. doi: 10.1128/AAC.38.9.2003.
9
In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori.利奈唑胺单独及与阿莫西林、克拉霉素和甲硝唑联合应用对幽门螺杆菌的体外活性。
Antimicrob Agents Chemother. 2000 Jul;44(7):1977-9. doi: 10.1128/AAC.44.7.1977-1979.2000.
10
Effect of plaunotol in combination with clarithromycin or amoxicillin on Helicobacter pylori in vitro and in vivo.普伐他汀与克拉霉素或阿莫西林联合使用对幽门螺杆菌的体内外作用
J Antimicrob Chemother. 2002 Jul;50(1):133-6. doi: 10.1093/jac/dkf094.
引用本文的文献
1
Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects.健康受试者中阿莫西林、克拉霉素与钾竞争性酸阻滞剂YH4808之间的药代动力学相互作用评估。
Transl Clin Pharmacol. 2020 Mar;28(1):55-65. doi: 10.12793/tcp.2020.28.e5. Epub 2020 Mar 31.
2
In vitro activities of a new ketolide, ABT-773, alone and in combination with amoxicillin, metronidazole, or tetracycline against Helicobacter pylori.新型酮内酯类药物ABT-773单独及与阿莫西林、甲硝唑或四环素联合应用对幽门螺杆菌的体外活性
Antimicrob Agents Chemother. 2000 Sep;44(9):2518-20. doi: 10.1128/AAC.44.9.2518-2520.2000.
3
Competition of various beta-lactam antibiotics for the major penicillin-binding proteins of Helicobacter pylori: antibacterial activity and effects on bacterial morphology.多种β-内酰胺类抗生素对幽门螺杆菌主要青霉素结合蛋白的竞争作用：抗菌活性及对细菌形态的影响
Antimicrob Agents Chemother. 1999 Nov;43(11):2702-9. doi: 10.1128/AAC.43.11.2702.
4
Activities of beta-lactams and macrolides against Helicobacter pylori.β-内酰胺类和大环内酯类抗生素对幽门螺杆菌的活性。
Antimicrob Agents Chemother. 1999 Jun;43(6):1387-92. doi: 10.1128/AAC.43.6.1387.
本文引用的文献
1
Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology.共识会议。消化性溃疡疾病的医学治疗。实践指南。美国胃肠病学会实践参数委员会。
JAMA. 1996 Feb 28;275(8):622-9. doi: 10.1001/jama.275.8.622.
2
Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori.
J Antimicrob Chemother. 1994 Dec;34(6):1025-9. doi: 10.1093/jac/34.6.1025.
3
The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.抗生素和抗溃疡药物对幽门弯曲菌的最低抑菌浓度和杀菌浓度。
J Antimicrob Chemother. 1986 Mar;17(3):309-14. doi: 10.1093/jac/17.3.309.
4
In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).枸橼酸铋与多种抗菌剂对幽门弯曲菌（幽门螺杆菌）的体外协同活性。
Antimicrob Agents Chemother. 1987 Sep;31(9):1429-30. doi: 10.1128/AAC.31.9.1429.
5
Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones.幽门螺杆菌对大环内酯类和氟喹诺酮类药物的敏感性。
J Antimicrob Chemother. 1988 Nov;22(5):631-6. doi: 10.1093/jac/22.5.631.
6
The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori.
Zentralbl Bakteriol. 1989 Sep;271(3):304-10. doi: 10.1016/s0934-8840(89)80028-3.
7
The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics.
J Clin Gastroenterol. 1990;12 Suppl 1:S135-8. doi: 10.1097/00004836-199001001-00023.
8
Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.14-羟基克拉霉素（克拉霉素在人体内的主要代谢产物）增强了克拉霉素对流感嗜血杆菌的体外和体内活性。
Antimicrob Agents Chemother. 1990 Jul;34(7):1407-13. doi: 10.1128/AAC.34.7.1407.
9
Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin.
Diagn Microbiol Infect Dis. 1992 Mar-Apr;15(3):259-66. doi: 10.1016/0732-8893(92)90122-a.
Zotero 插件